Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) 20% LOWER; reports a Q3 loss of $0.18, 6 cents better than the analyst estimate of ($0.24).
Revenue for the quarter was $3.1 million, which compares to the estimate of $3.04 million. The company expects that its current cash, cash equivalents and marketable securities can fund operations through at least the next twelve months.
AXT Inc (NASDAQ: AXTI) 19% HIGHER; reports Q3 EPS of $0.07, 9 cents better than the analyst estimate of ($0.02).
Revenue...
Post new comment